Skip to main
CMPS
CMPS logo

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways PLC has demonstrated a robust financial outlook, bolstered by a 95% probability of success for its proprietary psilocybin formulation, COMP360, following positive 6-week top-line data from the COMP005 study. The data indicated a clinically significant -3.6-point placebo-adjusted reduction on the MADRS scale, underscoring COMP360's potential effectiveness in treating treatment-resistant depression (TRD). Additionally, the company’s planned low-frequency dosing regimen for COMP360, requiring only 2-4 sessions per year, may increase its competitive edge over existing therapies, further enhancing its market prospects and appeal to patients and healthcare providers alike.

Bears say

Compass Pathways PLC has recently encountered challenges, as indicated by unexpected higher research and development (R&D) expenses related to advancing its COMP360 Phase 3 clinical trials, leading to a slight decrease in cash and cash equivalents from prior estimates. Potential competitive pressures could arise if rival companies produce compelling data in similar therapeutic areas, which may negatively affect the stock's valuation. Additionally, a strategic reorganization that resulted in decreased personnel has not fully alleviated financial strains, suggesting ongoing volatility and uncertainties surrounding the company's future performance and market positioning.

COMPASS Pathways (CMPS) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Buy based on their latest research and market trends.

According to 8 analysts, COMPASS Pathways (CMPS) has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.